Cerebral Protection in Transcatheter Left Atrial Appendage Occlusion (LAAC-SBI)
Primary Purpose
Atrial Fibrillation, Silent Stroke, Cognitive Impairment
Status
Recruiting
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
LAAC procedure with the use of transcatheter cerebral protection system
LAAC procedure without the use of transcatheter cerebral protection system
Sponsored by
About this trial
This is an interventional prevention trial for Atrial Fibrillation focused on measuring cerebral protection, left atrial appendage occlusion, atrial fibrillation, silent brain ischemia, cognitive impairment, depression
Eligibility Criteria
Inclusion Criteria:
- Documented permanent, persistent, or paroxysmal atrial fibrillation
- CHA2DS2VASc risk of stroke ≥2
- Contraindications to the use of anticoagulants or HSBLED bleeding risk ≥3
Exclusion Criteria:
- Dementia syndrome
- History of ischemic stroke
- Chronic abuse of psychoactive substances, including alcohol
- Mental diseases (including depression, bipolar disorder)
- The use of antidepressants
- Previous infections of the central nervous system, including neuroborreliosis
- Parkinson's disease
- Huntington's chorea
- Creutzfeld-Jakob disease
- Pick's disease
- Significant atherosclerosis of the cephalic arteries (> 70% LCCA or the brachiocephalic trunk)
- Strictures, ectasias, dissection or aneurysms at the exit of the LCCA or the brachiocephalic trunk from the aorta and up to 3 cm above
- Advancement of vascular changes in DW MRI of the head, grade 3 on the Fazekas scale
- Presence of a thrombus or tumours of a different nature in the left atrium or its ear
- Presence of a thrombus in the left ventricle
- Left atrial appendage anatomy preventing the use of occluders to close the left atrium appendage
- The presence of mechanical heart valve prostheses
- The state after the operative closure of the defect in the atrial septum
- Condition after closing the defect in the interatrial septum with the use of occluders
- Infective endocarditis
- Presence of devices and prostheses that prevent the performance of MRI (pacemakers, clips in the CNS)
- Status after oesophagal surgery
- Esophageal diverticula
- Esophageal varices> grade 3
- Sensitization to contrast agents
Sites / Locations
- Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwesryeteu Medycznego
- Klinika Chorób Serca i Naczyń, Krakowski Szpital Specjalistyczny im. Jana Pawła II
- I Klinika Kardiologii Katedry Kardiologii UM im. Karola Marcinkowskiego w Poznaniu, Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu
- Klinika Kardiologii i Chorób Wewnętrznych, Wojskowy Instytut Medyczny
- Klinika Choroby Wieńcowej i Strukturalnych Chorób Serca, Narodowy Instytut Kardiologii Stefana kardynała Wyszyńskiego - Państwowy Instytut Badawczy
- Silesian Centre for HEart Diseases in ZabrzeRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
LAAC with neuroprotection
LAAC without neuroprotection
Arm Description
Arm in which is used a transcatheter system to protect the cerebral circulation during the left atrial appendage closure procedures.
Arm in which the left atrial appendage closure procedures are performed without transcatheter cerebral protection.
Outcomes
Primary Outcome Measures
Change in number of silent cerebral ischemia (SBI) foci
number of SBI foci in DW MRI of the brain
Change in volume of silent cerebral ischemia (SBI) foci
volume SBI foci in DW MRI of the brain
Secondary Outcome Measures
Deterioration of cognitive functions
Montreal Cognitive Assessment (MoCA) test (scoring 0-30; cut-off value <26)
Deterioration of cognitive functions
The Trail Making Test Part A and B for Dementia (TMT A&B) - incorrect values: for part A > 70 sec. and for part B> 273 sec.
Development of dementia
diagnosis made by a specialist neurologist
Occurrence of depressive disorders
Hemiltona depression scale - 0 to 50 point, the higher the score, the more severe the mood disorder
Presence of embolic material in the filters of the neuroprotection device
Full Information
NCT ID
NCT05369195
First Posted
March 15, 2022
Last Updated
September 26, 2023
Sponsor
Silesian Centre for Heart Diseases
Collaborators
Leszek Giec Upper-Silesian Medical Centre, Medical University of Silesia, Biostat Sp. z o.o.
1. Study Identification
Unique Protocol Identification Number
NCT05369195
Brief Title
Cerebral Protection in Transcatheter Left Atrial Appendage Occlusion
Acronym
LAAC-SBI
Official Title
Cerebral Protection in Transcatheter Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 26, 2023 (Actual)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
September 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Silesian Centre for Heart Diseases
Collaborators
Leszek Giec Upper-Silesian Medical Centre, Medical University of Silesia, Biostat Sp. z o.o.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The study aims to assess the effect of the use of neuroprotection in transcutaneous occlusion of the left atrial appendage in patients with atrial fibrillation on the risk of perioperative silent brain ischemia and associated cognitive impairment and depression.
Detailed Description
Introduction: Left atrial appendage occlusion (LAAC) procedure is a method of preventing stroke in patients with atrial fibrillation who cannot use anticoagulants. The number of patients undergoing LAAC treatment tends to increase. LAAC procedures effectively reduce the number of strokes, with a significant reduction in the risk of bleeding compared to oral anticoagulants. However, although LAAC treatments alone have a low risk of perioperative stroke, some patients may experience incidents of silent brain ischemia (SBI). The distant effect of SBI may be cognitive deterioration, the onset of dementia syndromes, as well as depression.
Purpose of the study: The study aims to assess the effect of the use of neuroprotection in transcutaneous occlusion of the left atrial appendage (LAAC) in patients with atrial fibrillation on the risk of perioperative SBI and associated cognitive impairment and depression.
Methodology: The planned study is a prospective, multicentre, randomized, and double-blind intervention trial. Neuroprotection introduced from arterial access will be used in the LAAC treatment study group. In the control group, LAAC treatments will be performed without neuroprotection. Two hundred forty patients are planned to be enrolled with indications for stroke prevention due to atrial fibrillation. The analysis will include data obtained from DW MRI images, neurological evaluation results along with NIHSS-scale scores, results of cognitive evaluation tests (MoCA, COWAT, TMT A&B), and test of mood disorders (HADS Scale), as well as results of the EQ-5D-5L quality of life assessment questionnaire. It is planned to observe patients participating in the study for 24 months after LAAC procedure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation, Silent Stroke, Cognitive Impairment, Depression
Keywords
cerebral protection, left atrial appendage occlusion, atrial fibrillation, silent brain ischemia, cognitive impairment, depression
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Masking Description
In order to blind the radial artery will also be punctured in control group and an aortography will be performed. Researchers participating in the randomization of patients and in the procedure will not be included in the remaining stages of the study.
Allocation
Randomized
Enrollment
240 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
LAAC with neuroprotection
Arm Type
Experimental
Arm Description
Arm in which is used a transcatheter system to protect the cerebral circulation during the left atrial appendage closure procedures.
Arm Title
LAAC without neuroprotection
Arm Type
Placebo Comparator
Arm Description
Arm in which the left atrial appendage closure procedures are performed without transcatheter cerebral protection.
Intervention Type
Procedure
Intervention Name(s)
LAAC procedure with the use of transcatheter cerebral protection system
Intervention Description
After aortography the cerebral protection system will be delivered to cerebral arteries through radial access before accessing the left atrium.
Intervention Type
Procedure
Intervention Name(s)
LAAC procedure without the use of transcatheter cerebral protection system
Intervention Description
Only the aortography through radial access will be done before accessing the left atrium.
Primary Outcome Measure Information:
Title
Change in number of silent cerebral ischemia (SBI) foci
Description
number of SBI foci in DW MRI of the brain
Time Frame
change in the period up to 24 months
Title
Change in volume of silent cerebral ischemia (SBI) foci
Description
volume SBI foci in DW MRI of the brain
Time Frame
change in the period up to 24 months
Secondary Outcome Measure Information:
Title
Deterioration of cognitive functions
Description
Montreal Cognitive Assessment (MoCA) test (scoring 0-30; cut-off value <26)
Time Frame
prior to procedure, discharge (up to 5 days), 90 days, 12 months, 24 months
Title
Deterioration of cognitive functions
Description
The Trail Making Test Part A and B for Dementia (TMT A&B) - incorrect values: for part A > 70 sec. and for part B> 273 sec.
Time Frame
prior to procedure, discharge (up to 5 days), 90 days, 12 months, 24 months
Title
Development of dementia
Description
diagnosis made by a specialist neurologist
Time Frame
prior to procedure, discharge (up to 5 days), 90 days, 12 months, 24 months
Title
Occurrence of depressive disorders
Description
Hemiltona depression scale - 0 to 50 point, the higher the score, the more severe the mood disorder
Time Frame
prior to procedure, discharge (up to 5 days), 90 days, 12 months, 24 months
Title
Presence of embolic material in the filters of the neuroprotection device
Time Frame
during LAAC procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 Years and older
Subject able to provide signed informed consent.
Documented permanent, persistent, or paroxysmal atrial fibrillation
CHA2DS2VASc risk of stroke ≥2
At least one of the following criteria:
Contraindications to the use of anticoagulants,
HSBLED bleeding risk ≥3
Exclusion Criteria:
Serious mental diseases, particularly: dementia syndrome of any etiology, schizophrenia,schizoaffective disorders, bipolar disorder
History of ischemic stroke
Chronic abuse of alcohol or any other psychoactive substances except for nicotine
long-term therapy with benzodiazepines
The use of antidepressants in 3 months prior inclusion.
Previous infections of the central nervous system, including neuroborreliosis
Parkinson's disease
Huntington's chorea
Creutzfeld-Jakob disease
Pick's disease
Significant atherosclerosis of the cephalic arteries (> 70% LCCA or the brachiocephalic trunk)
Strictures, ectasias, dissection or aneurysms at the exit of the LCCA or the brachiocephalic trunk from the aorta and up to 3 cm above
Advancement of vascular changes in DW MRI of the head, grade 3 on the Fazekas scale
Presence of a thrombus or tumours of a different nature in the left atrium or its ear
Presence of a thrombus in the left ventricle
Left atrial appendage anatomy preventing the use of occluders to close the left atrium appendage
The presence of mechanical heart valve prostheses
The state after the operative closure of the defect in the atrial septum
Condition after closing the defect in the interatrial septum with the use of occluders
Active infective endocarditis
Presence of devices and prostheses that prevent the performance of MRI (pacemakers, clips in the CNS)
Status after oesophagal surgery
Esophageal diverticula
Esophageal varices> grade 3
Allergic to contrast agents
A contraindication to use antiplatelet drugs
Diagnosis of neoplastic disease with estimated survival beyond 1 year
Clininally evident hypothyroidism and hyperthyroidism
Klaustrofobia
Pregnancy
AIDS
Participation in other drug research studies
The presence of circumstances or any medical condition the Investigator considers problematic for subject inclusion, or test results that may couse problems to provide reliable, acurate to interpretation results
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Witold A Streb, Ph.D.
Phone
0048322713414
Email
w.streb@sccs.pl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zbigniew F Kalarus, Prof.
Organizational Affiliation
Silesian Centre for Heart Diseases in Zabrze
Official's Role
Principal Investigator
Facility Information:
Facility Name
Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwesryeteu Medycznego
City
Katowice
ZIP/Postal Code
40-635
Country
Poland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Klaudia Rogowska
Phone
+48 32 3598313
Email
dyrektor@gcm.pl
First Name & Middle Initial & Last Name & Degree
Wojciech Wojakowski, Prof.
Phone
+48 32 252 39 30
Email
wwojakowski@sum.edu.pl
First Name & Middle Initial & Last Name & Degree
Wojciech Wojakowski, Prof.
Facility Name
Klinika Chorób Serca i Naczyń, Krakowski Szpital Specjalistyczny im. Jana Pawła II
City
Kraków
ZIP/Postal Code
31-202
Country
Poland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tadeusz Przewłocki, Prof.
Email
tadeuszprzewlocki@op.pl
First Name & Middle Initial & Last Name & Degree
Tadeusz Przewłocki, Prof.
Facility Name
I Klinika Kardiologii Katedry Kardiologii UM im. Karola Marcinkowskiego w Poznaniu, Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu
City
Poznań
ZIP/Postal Code
61-848
Country
Poland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marek Grygier, Prof.
Email
marek.grygier@skpp.edu.pl
First Name & Middle Initial & Last Name & Degree
Marek Grygier
Facility Name
Klinika Kardiologii i Chorób Wewnętrznych, Wojskowy Instytut Medyczny
City
Warszawa
ZIP/Postal Code
04-141
Country
Poland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Piotr Kwiatkowski, MD
Email
pkwiatkowski@wim.mil.pl
First Name & Middle Initial & Last Name & Degree
Piotr Kwiatkowski, MD
Facility Name
Klinika Choroby Wieńcowej i Strukturalnych Chorób Serca, Narodowy Instytut Kardiologii Stefana kardynała Wyszyńskiego - Państwowy Instytut Badawczy
City
Warszawa
ZIP/Postal Code
04-625
Country
Poland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marcin Demkow, Prof.
Email
m.demkow@ikard.pl
First Name & Middle Initial & Last Name & Degree
Marcin Demkow, Prof.
Facility Name
Silesian Centre for HEart Diseases in Zabrze
City
Zabrze
ZIP/Postal Code
41-800
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Witold Streb, Ph.D
Phone
+48 32 2713414
Email
w.streb@sccs.pl
First Name & Middle Initial & Last Name & Degree
Zbigniew Kalarus, Prof.
Phone
+48 32 37 33 682
Email
karzab@sum.edu.pl
First Name & Middle Initial & Last Name & Degree
Zbigniew Kalarus, Prof
First Name & Middle Initial & Last Name & Degree
Witold Streb, Ph.D
First Name & Middle Initial & Last Name & Degree
Katarzyna Mitręga, MD
First Name & Middle Initial & Last Name & Degree
Wiktoria Kowalska, MD
First Name & Middle Initial & Last Name & Degree
Monika Kozioł, MD
First Name & Middle Initial & Last Name & Degree
Tomasz Podolecki, Ph.D.
First Name & Middle Initial & Last Name & Degree
Agata Sobczyk, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Cerebral Protection in Transcatheter Left Atrial Appendage Occlusion
We'll reach out to this number within 24 hrs